| Autor: |
Saratikov AS; Pharmacology Department, Siberian Medical University, Moskovskii trakt 2, Tomsk, 634050 Russia. albert@post.tomica.ru, Livshits NS, Burchenkova FI, Kadychagova NG, Akhmedzhanov RR, Bashirova LV |
| Jazyk: |
ruština |
| Zdroj: |
Eksperimental'naia i klinicheskaia farmakologiia [Eksp Klin Farmakol] 2003 Nov-Dec; Vol. 66 (6), pp. 53-5. |
| Abstrakt: |
The results of preclinical safety evaluation of the new hepatoprotector maxar showed that this drug can be classified as a low-toxicity substance with respect to acute toxicity. No significant functional and structural changes in the systems and organs of experimental animals were observed after a 6-month administration in rats (in a dose of 300, 600, and 1200 mg/kg) and in dogs (500 mg/kg). Maxar exhibited no mutagen and allergen properties, produced no immunotoxicant action, and did not adversely affect the reproduction function. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
